Latest News about AMGN
Recent news which mentions AMGN
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
From Benzinga
These four Dow stocks take top prizes for dividend growth
September 06, 2023
From MarketWatch
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
September 05, 2023
From Benzinga
Should You Still Buy the Dow Jones' Best-Performing August Stocks?
September 05, 2023
From Motley Fool
The 3 Most Promising Dow Stocks to Own Now
September 03, 2023
From InvestorPlace
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
From Motley Fool
As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs
September 01, 2023
From MarketWatch
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
September 01, 2023
From Benzinga
FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics
September 01, 2023
From MarketWatch
Is This the Green Light Biotech Stocks Have Been Waiting For?
August 31, 2023
From Motley Fool
From Motley Fool
From MarketWatch
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
August 29, 2023
From Benzinga
From Benzinga
Nasdaq, S&P 500 Futures Flatline Ahead Of JOLTS, House Price Data; Why This Analyst Recommends 'Buying Weakness Than Selling Rallies'
August 29, 2023
From Benzinga
From Benzinga
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
From Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
August 28, 2023
From Benzinga
US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals
August 28, 2023
From Benzinga
From Benzinga
As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit — even if their drugs aren’t on the list
August 25, 2023
From MarketWatch
From MarketWatch
4 Surefire Stocks to Buy in the Next Bear Market
August 24, 2023
From Motley Fool
From Benzinga
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
August 21, 2023
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.